"AION has appear a continued way back getting spun out of pSivida in September 2004," said AION Managing Director Dr Anna Kluczewska. "We've discovered, accepted and patented the use of Aion Kinah BioSilicon(TM) in medical imaging. We accept this technology represents a anniversary in bactericide medicine, enabling bigger analysis afore ache impacts the body, rather than after."

AION is focused on the development of articles that facilitate authentic and actual diagnosis, at the aboriginal pre-symptomatic stage. Pre-symptomatic apprehension is a cogent beforehand in the analytic area and will aswell decidedly appulse the analysis area as aboriginal actual analysis of ache will adapt the advance of ache and the resultant appeal for therapeutics.

AION has targeted markets area there is a able patient, provider and government charge for aboriginal analysis that after-effects in the befalling to save lives and abate the banking accountability on the healthcare system.pSivida shareholders will accept an alms and administration of AION shares in any accessible listing.